

# Bernd Neumaier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/203230/publications.pdf>

Version: 2024-02-01

227  
papers

8,572  
citations

34105

52  
h-index

56724

83  
g-index

235  
all docs

235  
docs citations

235  
times ranked

8919  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of [ <sup>18</sup> F]DCFPyL and [ <sup>68</sup> Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2015, 17, 575-584.	2.6	288
2	Imaging proliferation in lung tumors with PET: <sup>18</sup> F-FLT versus <sup>18</sup> F-FDG. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1426-31.	5.0	281
3	Early Detection and Accurate Description of Extent of Metastatic Bone Disease in Breast Cancer With Fluoride Ion and Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 1999, 17, 2381-2381.	1.6	266
4	Experience with carbon-11 choline positron emission tomography in prostate carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1415-1419.	2.1	206
5	Nucleophilic <sup>18</sup> F-Fluorination of Heteroaromatic Iodonium Salts with No-Carrier-Added [ <sup>18</sup> F]Fluoride. <i>Journal of the American Chemical Society</i> , 2007, 129, 8018-8025.	13.7	194
6	Molecular Imaging of Proliferation in Malignant Lymphoma. <i>Cancer Research</i> , 2006, 66, 11055-11061.	0.9	173
7	Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [ <sup>18</sup> F]Fluorodeoxyglucose and [ <sup>18</sup> F]Fluorothymidine Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2011, 29, 1701-1708.	1.6	170
8	Sleep Deprivation Increases A1 Adenosine Receptor Binding in the Human Brain: A Positron Emission Tomography Study. <i>Journal of Neuroscience</i> , 2007, 27, 2410-2415.	3.6	169
9	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 1732-1740.	8.2	166
10	<sup>3</sup> -deoxy-3-[( <sup>18</sup> F)fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. <i>Cancer Research</i> , 2002, 62, 3331-4.	0.9	162
11	PSA-Stratified Performance of <sup>18</sup> F- and <sup>68</sup> Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 947-952.	5.0	150
12	Assessment of <sup>18</sup> F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. <i>JAMA Neurology</i> , 2020, 77, 1408.	9.0	145
13	Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1380-1384.	6.4	144
14	Networks of tau distribution in Alzheimer's disease. <i>Brain</i> , 2018, 141, 568-581.	7.6	140
15	Glioma Proliferation as Assessed by <sup>3</sup> -Fluoro- <sup>3</sup> -Deoxy- <sup>3</sup> -Thymidine Positron Emission Tomography in Patients with Newly Diagnosed High-Grade Glioma. <i>Clinical Cancer Research</i> , 2008, 14, 2049-2055.	7.0	129
16	<sup>3</sup> '-[ <sup>18</sup> F]fluoro- <sup>3</sup> '-deoxythymidine ([ <sup>18</sup> F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. <i>Cancer Research</i> , 2003, 63, 2681-7.	0.9	128
17	In vivo imaging of activated microglia using [ <sup>11</sup> C]PK11195 and positron emission tomography in patients after ischemic stroke. <i>NeuroReport</i> , 2000, 11, 2957-2960.	1.2	121
18	Neuroinflammation Extends Brain Tissue at Risk to Vital Peri-Infarct Tissue: A Double Tracer [ <sup>11</sup> C]PK11195- and [ <sup>18</sup> F]FDG-PET Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1216-1225.	4.3	114

#	ARTICLE	IF	CITATIONS
19	Copper-Mediated Aromatic Radiofluorination Revisited: Efficient Production of PET Tracers on a Preparative Scale. <i>Chemistry - A European Journal</i> , 2015, 21, 5972-5979.	3.3	113
20	Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis. <i>NeuroImage: Clinical</i> , 2018, 20, 537-542.	2.7	113
21	New developments in the production of theranostic pairs of radionuclides. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2018, 318, 1493-1509.	1.5	112
22	Alcohol-Enhanced Cu-Mediated Radiofluorination. <i>Chemistry - A European Journal</i> , 2017, 23, 3251-3256.	3.3	104
23	Clinical relevance of imaging proliferative activity in lung nodules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 525-533.	6.4	101
24	Noninvasive Imaging of Endogenous Neural Stem Cell Mobilization <i>In Vivo</i> Using Positron Emission Tomography. <i>Journal of Neuroscience</i> , 2010, 30, 6454-6460.	3.6	97
25	Cholinergic system function and cognition in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2012, 33, 867-877.	3.1	96
26	Static and dynamic <sup>18</sup> F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 443-451.	6.4	95
27	In vivo Patterns of Tau Pathology, Amyloid- $\beta$ Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 465-471.	2.6	93
28	<sup>188</sup> Re or <sup>90</sup> Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. <i>British Journal of Haematology</i> , 2005, 130, 604-613.	2.5	92
29	Predicting IDH genotype in gliomas using FET PET radiomics. <i>Scientific Reports</i> , 2018, 8, 13328.	3.3	90
30	Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 934-939.	3.7	89
31	Diagnostic potential of PET/CT using a <sup>68</sup> Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 102-107.	6.4	87
32	Neither azeotropic drying, nor base nor other additives: a minimalist approach to <sup>18</sup> F-labeling. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 8094-8099.	2.8	86
33	Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase <sup>18</sup> F-FET PET accuracy without dynamic scans. <i>European Radiology</i> , 2017, 27, 2916-2927.	4.5	81
34	Early Detection of Erlotinib Treatment Response in NSCLC by <sup>3</sup> -Deoxy- <sup>3</sup> -[ <sup>18</sup> F]-Fluoro-L-Thymidine ([ <sup>18</sup> F]FLT) Positron Emission Tomography (PET). <i>PLoS ONE</i> , 2008, 3, e3908.	2.5	80
35	Clinical Value of <sup>18</sup> -Fluorine-Fluorodihydroxyphenylalanine Positron Emission Tomography/Computed Tomography in the Follow-Up of Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2010, 20, 527-533.	4.5	78
36	Transcranial direct current stimulation accelerates recovery of function, induces neurogenesis and recruits oligodendrocyte precursors in a rat model of stroke. <i>Experimental Neurology</i> , 2016, 279, 127-136.	4.1	77

#	ARTICLE	IF	CITATIONS
37	Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[ <sup>18</sup> F]Tj)ETQq1 1 0.784314 rgBT / Overlock	3.8	76
38	FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 591-602.	6.4	74
39	Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 958-966.	2.1	71
40	Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[ <sup>18</sup> F]fluoro-3'-deoxythymidine ([ <sup>18</sup> F]FLT) in pancreatic cancer cell lines. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1174-1181.	6.4	70
41	Iodonium ylides for one-step, no-carrier-added radiofluorination of electron rich arenes, exemplified with 4-([ <sup>18</sup> F]fluorophenoxy)-phenylmethyl)piperidine NET and SERT ligands. <i>RSC Advances</i> , 2014, 4, 17293-17299.	3.6	70
42	Aromatic-turmerone induces neural stem cell proliferation in vitro and in vivo. <i>Stem Cell Research and Therapy</i> , 2014, 5, 100.	5.5	69
43	Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non-Small Cell Lung Cancer Using <sup>18</sup> F-FDG and <sup>3</sup> -Deoxy- <sup>3</sup> - <sup>18</sup> F-Fluorothymidine PET. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1871-1877.	5.0	65
44	Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease. <i>Brain</i> , 2018, 141, 903-915.	7.6	65
45	Three-Step, One-Pot Radiosynthesis of 6-Fluoro-3,4-Dihydroxy-l-Phenylalanine by Isotopic Exchange. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1724-1729.	5.0	63
46	Early assessment of therapy response in malignant lymphoma with the thymidine analogue [ <sup>18</sup> F]FLT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1775-1782.	6.4	62
47	Clinical value of <sup>18</sup> F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography ( <sup>18</sup> F-DOPA PET/CT) for detecting pheochromocytoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 484-493.	6.4	62
48	Discovery of [ <sup>18</sup> F]Fluorotryptophan as a Novel Positron Emission Tomography (PET) Probe for the Visualization of Tryptophan Metabolism in Vivo. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 189-206.	6.4	61
49	Progression of subtle motor signs in <i>PINK1</i> mutation carriers with mild dopaminergic deficit. <i>Neurology</i> , 2010, 74, 1798-1805.	1.1	60
50	Noninvasive quantification of <sup>18</sup> F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1960-1967.	6.4	59
51	Intraindividual Comparison of <sup>18</sup> F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 729-734.	5.0	58
52	Direct comparison of [ <sup>18</sup> F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1355-1364.	6.4	53
53	Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 351-354.	3.1	52
54	Glucose consumption of inflammatory cells masks metabolic deficits in the brain. <i>NeuroImage</i> , 2016, 128, 54-62.	4.2	52

#	ARTICLE	IF	CITATIONS
55	Uses of alpha particles, especially in nuclear reaction studies and medical radionuclide production. <i>Radiochimica Acta</i> , 2016, 104, 601-624.	1.2	52
56	In vivo analysis of neuroinflammation in the late chronic phase after experimental stroke. <i>Neuroscience</i> , 2015, 292, 71-80.	2.3	49
57	Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1265-1273.	6.4	48
58	Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 90S-96S.	5.0	48
59	Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non-Small Cell Lung Cancer Treated With Erlotinib. <i>Clinical Nuclear Medicine</i> , 2012, 37, 1058-1064.	1.3	47
60	Effects of minocycline on endogenous neural stem cells after experimental stroke. <i>Neuroscience</i> , 2012, 215, 174-183.	2.3	47
61	The Functional Networks of Prepulse Inhibition: Neuronal Connectivity Analysis Based on FDG-PET in Awake and Unrestrained Rats. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 148.	2.0	47
62	Circadian variation of metabotropic glutamate receptor 5 availability in the rat brain. <i>Journal of Sleep Research</i> , 2016, 25, 754-761.	3.2	47
63	Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1117-1127.	6.4	43
64	In-vivo detection of inflammation and neurodegeneration in the chronic phase after permanent embolic stroke in rats. <i>Brain Research</i> , 2014, 1581, 80-88.	2.2	43
65	On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion. <i>Nuclear Medicine and Biology</i> , 2021, 93, 19-21.	0.6	43
66	Discovery of <sup>18</sup> F-JK-PSMA-7, a PET Probe for the Detection of Small PSMA-Positive Lesions. <i>Journal of Nuclear Medicine</i> , 2019, 60, 817-823.	5.0	41
67	Imaging of activated microglia with PET and [ <sup>11</sup> C]PK 11195 in corticobasal degeneration. <i>Movement Disorders</i> , 2004, 19, 817-821.	3.9	39
68	Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. <i>Science Advances</i> , 2021, 7, eabh2399.	10.3	39
69	Analysis of the Growth Dynamics of Angiogenesis-Dependent and -Independent Experimental Glioblastomas by Multimodal Small-Animal PET and MRI. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1135-1145.	5.0	38
70	<sup>18</sup> F-labelling innovations and their potential for clinical application. <i>Clinical and Translational Imaging</i> , 2018, 6, 169-193.	2.1	37
71	[ <sup>18</sup> F]-Deoxy- <sup>3</sup> -Fluorothymidine-PET in NHL Patients: Whole-Body Biodistribution and Imaging of Lymphoma Manifestations – a Pilot Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 436-442.	1.0	37
72	Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 807-815.	2.1	36

#	ARTICLE	IF	CITATIONS
73	White matter lesions and the cholinergic deficit in aging and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2017, 53, 27-35.	3.1	36
74	Novel CDTA-based, Bifunctional Chelators for Stable and Inert Mn <sup>II</sup> Complexation: Synthesis and Physicochemical Characterization. <i>Inorganic Chemistry</i> , 2017, 56, 7746-7760.	4.0	36
75	Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib. <i>PLoS ONE</i> , 2013, 8, e53081.	2.5	36
76	Lymph Node Staging in Lung Cancer Using [18F]FDG-PET. <i>Thoracic and Cardiovascular Surgeon</i> , 2004, 52, 96-101.	1.0	35
77	[18F] 3-deoxy-3- <sup>2</sup> -fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18F]-fluoro-2-deoxy- d -glucose positron emission tomography in the workup of suspicious central focal lesions?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2004, 127, 1093-1099.	0.8	33
78	Whiskers Area as Extracerebral Reference Tissue for Quantification of Rat Brain Metabolism Using <sup>18</sup> F-FDG PET: Application to Focal Cerebral Ischemia. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1252-1260.	5.0	33
79	Potential of Early [ <sup>18</sup> F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography for Identifying Hypoperfusion and Predicting Fate of Tissue in a Rat Embolic Stroke Model. <i>Stroke</i> , 2012, 43, 193-198.	2.0	32
80	Beyond azide-alkyne click reaction: easy access to 18F-labelled compounds via nitrile oxide cycloadditions. <i>Chemical Communications</i> , 2012, 48, 7134.	4.1	30
81	The integrity of the cholinergic system determines memory performance in healthy elderly. <i>NeuroImage</i> , 2014, 100, 481-488.	4.2	30
82	A Practical One-Pot Synthesis of Positron Emission Tomography (PET) Tracers via Nickel-Mediated Radiofluorination. <i>ChemistryOpen</i> , 2015, 4, 457-462.	1.9	30
83	A Practical Method for the Preparation of 18F-Labeled Aromatic Amino Acids from Nucleophilic [18F]Fluoride and Stannyl Precursors for Electrophilic Radiohalogenation. <i>Molecules</i> , 2017, 22, 2231.	3.8	30
84	Current trends in the use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in neurooncology. <i>Nuclear Medicine and Biology</i> , 2021, 92, 78-84.	0.6	30
85	Binding characteristics of [ <sup>18</sup> F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2957-2972.	4.3	30
86	A fully automated two-step synthesis of an 18F-labelled tyrosine kinase inhibitor for EGFR kinase activity imaging in tumors. <i>Applied Radiation and Isotopes</i> , 2009, 67, 1977-1984.	1.5	27
87	Influence of Bevacizumab on Blood-Brain Barrier Permeability and <sup>18</sup> F-Fluoroethyl-L-Tyrosine Uptake in Rat Gliomas. <i>Journal of Nuclear Medicine</i> , 2017, 58, 700-705.	5.0	27
88	Evaluation of 18F-Labeled Benzodioxine Piperazine-Based Dopamine D4 Receptor Ligands: Lipophilicity as a Determinate of Nonspecific Binding. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 8343-8352.	6.4	26
89	Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer. <i>Cancer Research</i> , 2014, 74, 2816-2824.	0.9	26
90	Preparation of No-Carrier-Added [ <sup>18</sup> F]Fluoro-L-tryptophan via Cu-Mediated Radiofluorination. <i>European Journal of Organic Chemistry</i> , 2016, 2016, 4621-4628.	2.4	26

#	ARTICLE	IF	CITATIONS
91	Automated synthesis of 4-[ <sup>18</sup> F]fluoroanisole, [ <sup>18</sup> F]DAA1106 and 4-[ <sup>18</sup> F]FpHe using Cu-mediated radiofluorination under "minimalist" conditions. Applied Radiation and Isotopes, 2016, 115, 133-137.	1.5	26
92	Acute and Sustained Effects of Methylphenidate on Cognition and Presynaptic Dopamine Metabolism: An [ <sup>18</sup> F]FDOPA PET Study. Journal of Neuroscience, 2014, 34, 14769-14776.	3.6	24
93	Synthesis of <sup>18</sup> F-labelled $\beta$ -lactams by Using the Kinugasa Reaction. Chemistry - A European Journal, 2014, 20, 4697-4703.	3.3	24
94	Biodistribution and radiation dosimetry of [ <sup>18</sup> F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer. EJNMMI Research, 2019, 9, 66.	2.5	24
95	Synthesis, radiofluorination and first evaluation of ( $\pm$ )-[ <sup>18</sup> F]MDL 100907 as serotonin 5-HT <sub>2A</sub> receptor antagonist for PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 6-12.	1.0	23
96	An <sup>18</sup> F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with <sup>18</sup> F-JK-PSMA-7 During the First Year of Application. Journal of Nuclear Medicine, 2020, 61, 202-209.	5.0	23
97	Radiolabelling with isotopic mixtures of <sup>52</sup> g/ <sup>55</sup> g Mn( <sup>II</sup> ) as a straight route to stable manganese complexes for bimodal PET/MR imaging. Dalton Transactions, 2016, 45, 1315-1321.	3.3	22
98	Positron-emitting radionuclides for applications, with special emphasis on their production methodologies for medical use. Radiochimica Acta, 2019, 107, 1011-1026.	1.2	22
99	Feasibility of short imaging protocols for [ <sup>18</sup> F]PI-2620 tau-PET in progressive supranuclear palsy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3872-3885.	6.4	22
100	4-[ <sup>18</sup> F]Fluorophenylpiperazines by Improved Hartwig-Buchwald N-Arylation of 4-[ <sup>18</sup> F]fluoroiodobenzene, Formed via Hypervalent I <sub>3</sub> -Iodane Precursors: Application to Build-Up of the Dopamine D4 Ligand [ <sup>18</sup> F]FAUC 316. Molecules, 2015, 20, 470-486.	3.8	21
101	Influence of blood-brain barrier permeability on O-(2- <sup>18</sup> F-fluoroethyl)-L-tyrosine uptake in rat gliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 408-416.	6.4	21
102	Excitatory-inhibitory balance within EEG microstates and resting-state fMRI networks: assessed via simultaneous trimodal PET-MR-EEG imaging. Translational Psychiatry, 2021, 11, 60.	4.8	21
103	Neural correlates of sensorimotor gating: a metabolic positron emission tomography study in awake rats. Frontiers in Behavioral Neuroscience, 2014, 8, 178.	2.0	21
104	mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia. Human Brain Mapping, 2020, 41, 2762-2781.	3.6	20
105	Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatized thymidine analog. Nuclear Medicine and Biology, 2006, 33, 359-366.	0.6	19
106	Carrier effect on palladium-catalyzed, nucleophilic <sup>18</sup> F-fluorination of aryl triflates. Journal of Labelled Compounds and Radiopharmaceuticals, 2012, 55, 450-453.	1.0	19
107	Expanding PET-applications in life sciences with positron-emitters beyond fluorine-18. Nuclear Medicine and Biology, 2021, 92, 241-269.	0.6	19
108	Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget, 2015, 6, 38458-38468.	1.8	19

#	ARTICLE	IF	CITATIONS
109	Synthesis, labelling and first evaluation of [ <sup>18</sup> F]R91150 as a serotonin 5-HT <sub>2A</sub> receptor antagonist for PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2009, 52, 13-22.	1.0	18
110	The synthetic NCAM mimetic peptide FGL mobilizes neural stem cells in vitro and in vivo. <i>Stem Cell Reviews and Reports</i> , 2014, 10, 539-547.	5.6	18
111	One-Stop Shop: <sup>18</sup> F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases. <i>Journal of Nuclear Medicine</i> , 2021, 62, 240-246.	5.0	18
112	Drug Penetration into the Central Nervous System: Pharmacokinetic Concepts and In Vitro Model Systems. <i>Pharmaceutics</i> , 2021, 13, 1542.	4.5	18
113	The Neural Cell Adhesion Molecule-Derived (NCAM)-Peptide FG Loop (FGL) Mobilizes Endogenous Neural Stem Cells and Promotes Endogenous Regenerative Capacity after Stroke. <i>Journal of NeuroImmune Pharmacology</i> , 2016, 11, 708-720.	4.1	17
114	Continuing Nuclear Data Research for Production of Accelerator-Based Novel Radionuclides for Medical Use: A Mini-Review. <i>Frontiers in Physics</i> , 2021, 9, .	2.1	17
115	An <sup>89</sup> Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 573-583.	5.0	17
116	Labelling of a monoclonal antibody with <sup>68</sup> Ga using three DTPA-based bifunctional ligands and their in vitro evaluation for application in radioimmunotherapy. <i>Radiochimica Acta</i> , 2007, 95, 39-42.	1.2	16
117	C-(4-[ <sup>18</sup> F]fluorophenyl)-N-phenyl nitrene: A novel <sup>18</sup> F-labeled building block for metal free [3+2]cycloaddition. <i>Applied Radiation and Isotopes</i> , 2012, 70, 184-192.	1.5	16
118	Level of education mitigates the impact of tau pathology on neuronal function. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1787-1795.	6.4	16
119	Comparison of [ <sup>18</sup> F]Fluoroethyltyrosine PET and Sodium MRI in Cerebral Gliomas: a Pilot Study. <i>Molecular Imaging and Biology</i> , 2020, 22, 198-207.	2.6	16
120	Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[ <sup>18</sup> F]fluoroethyl)-l-tyrosine PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1486-1495.	6.4	16
121	Synthesis and evaluation of <sup>18</sup> F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease. <i>Applied Radiation and Isotopes</i> , 2010, 68, 1066-1072.	1.5	15
122	Conflict Processing in the Rat Brain: Behavioral Analysis and Functional <sup>18</sup> F-PET Imaging Using [ <sup>18</sup> F]Fluorodeoxyglucose. <i>Frontiers in Behavioral Neuroscience</i> , 2012, 6, 4.	2.0	15
123	Non-invasive imaging of glioma vessel size and densities in correlation with tumour cell proliferation by small animal PET and MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1595-1606.	6.4	15
124	Structural Prediction of the Dimeric Form of the Mammalian Translocator Membrane Protein TSPO: A Key Target for Brain Diagnostics. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2588.	4.1	15
125	ADORA2A variation and adenosine A1 receptor availability in the human brain with a focus on anxiety-related brain regions: modulation by ADORA1 variation. <i>Translational Psychiatry</i> , 2020, 10, 406.	4.8	15
126	Short Communication: <sup>18</sup> F-Immuno-PET: Determination of Anti-CD66 Biodistribution in a Patient with High-Risk Leukemia. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 819-824.	1.0	14



#	ARTICLE	IF	CITATIONS
127	Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET. <i>Lung Cancer</i> , 2012, 77, 617-620.	2.0	14
128	Radiosynthesis of 4-[18 F]fluoro-L-tryptophan by isotopic exchange on carbonyl-activated precursors. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5856-5869.	3.0	14
129	Motor impairment and compensation in a hemiparkinsonian rat model: correlation between dopamine depletion severity, cerebral metabolism and gait patterns. <i>EJNMMI Research</i> , 2017, 7, 68.	2.5	14
130	Accurate determination of production data of the non-standard positron emitter <sup>86</sup> Y via the <sup>86</sup> Sr(p,n)-reaction. <i>Radiochimica Acta</i> , 2020, 108, 747-756.	1.2	14
131	Validation of myocardial blood flow estimation with nitrogen-13 ammonia PET by the argon inert gas technique in humans. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 340-345.	2.1	13
132	The Bioenergetic Status Relates to Dopamine Neuron Loss in Familial PD with PINK1 Mutations. <i>PLoS ONE</i> , 2012, 7, e51308.	2.5	13
133	Role of Extracellular Loops and Membrane Lipids for Ligand Recognition in the Neuronal Adenosine Receptor Type 2A: An Enhanced Sampling Simulation Study. <i>Molecules</i> , 2018, 23, 2616.	3.8	13
134	Alcohol-Supported Cu-Mediated 18F-Fluorination of Iodonium Salts under "Minimalist" Conditions. <i>Molecules</i> , 2019, 24, 3197.	3.8	13
135	High uptake of 68Ga-PSMA and 18F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes. <i>EJNMMI Research</i> , 2020, 10, 55.	2.5	13
136	[18F]3'-Deoxy-3'-Fluorothymidine-PET in NHL Patients: Whole-Body Biodistribution and Imaging of Lymphoma Manifestations—a Pilot Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 436-442.	1.0	12
137	2-[18F]Fluorophenylalanine: Synthesis by Nucleophilic 18F-Fluorination and Preliminary Biological Evaluation. <i>Synthesis</i> , 2019, 51, 664-676.	2.3	12
138	Convenient PET-tracer production via SuFEx 18F-fluorination of nanomolar precursor amounts. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114383.	5.5	12
139	Novel ion exchange chromatography method for nca arsenic separation. <i>Applied Radiation and Isotopes</i> , 2017, 122, 111-115.	1.5	11
140	Influence of Dexamethasone on O-(2-[18F]-Fluoroethyl)-L-Tyrosine Uptake in the Human Brain and Quantification of Tumor Uptake. <i>Molecular Imaging and Biology</i> , 2019, 21, 168-174.	2.6	11
141	Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD. <i>NeuroImage: Clinical</i> , 2019, 24, 101978.	2.7	11
142	Minimalist approach meets green chemistry: Synthesis of <sup>18</sup> F-labeled (hetero)aromatics in pure ethanol. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 404-410.	1.0	11
143	Tc-99m-MIBI-Negative Parathyroid Adenoma in Primary Hyperparathyroidism Detected by C-11-Methionine PET/CT After Previous Thyroid Surgery. <i>Clinical Nuclear Medicine</i> , 2011, 36, 1153-1155.	1.3	10
144	Seyferth "Gilbert Homologation as a Route to <sup>18</sup> F-labeled Building Blocks: Preparation of Radiofluorinated Phenylacetyles and Their Application in PET Chemistry. <i>European Journal of Organic Chemistry</i> , 2016, 2016, 430-433.	2.4	10

#	ARTICLE	IF	CITATIONS
145	Convenient Preparation of <sup>18</sup> F-Labeled Peptide Probes for Potential Claudin-4 PET Imaging. <i>Pharmaceuticals</i> , 2017, 10, 99.	3.8	10
146	Relevance of In Vitro Metabolism Models to PET Radiotracer Development: Prediction of In Vivo Clearance in Rats from Microsomal Stability Data. <i>Pharmaceuticals</i> , 2019, 12, 57.	3.8	10
147	Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics. <i>Pharmaceutics</i> , 2020, 12, 1247.	4.5	10
148	Preparation of labeled aromatic amino acids via late-stage <sup>18</sup> F-fluorination of chiral nickel and copper complexes. <i>Chemical Communications</i> , 2020, 56, 9505-9508.	4.1	10
149	Flare Phenomenon in O-(2- <sup>18</sup> F-Fluoroethyl)-L-Tyrosine PET After Resection of Gliomas. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1294-1299.	5.0	10
150	Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2022, 24, 115-125.	2.6	10
151	Assessment of the In Vivo Relationship Between Cerebral Hypometabolism, Tau Deposition, TSPO Expression, and Synaptic Density in a Tauopathy Mouse Model: a Multi-tracer PET Study. <i>Molecular Neurobiology</i> , 2022, 59, 3402-3413.	4.0	10
152	Longitudinal assessment of infarct progression, brain metabolism and behavior following anterior cerebral artery occlusion in rats. <i>Journal of Neuroscience Methods</i> , 2015, 253, 279-291.	2.5	9
153	Uptake in non-affected bone tissue does not differ between [ <sup>18</sup> F]-DCFPyL and [ <sup>68</sup> Ga]-HBED-CC PSMA PET/CT. <i>PLoS ONE</i> , 2018, 13, e0209613.	2.5	9
154	Simultaneous PET-MR-EEG: Technology, Challenges and Application in Clinical Neuroscience. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2019, 3, 377-385.	3.7	9
155	Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands. <i>European Journal of Medicinal Chemistry</i> , 2021, 214, 113214.	5.5	9
156	Nondestructive monitoring of tissue-engineered constructs. <i>Biomedizinische Technik</i> , 2014, 59, 165-75.	0.8	8
157	The use of O-(2- <sup>18</sup> F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord. <i>Neuro-Oncology</i> , 2016, 19, now243.	1.2	8
158	Effects of subthalamic deep brain stimulation on striatal metabolic connectivity in a rat hemiparkinsonian model. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	2.4	8
159	Preparation of a First <sup>18</sup> F-Labeled Agonist for M1 Muscarinic Acetylcholine Receptors. <i>Molecules</i> , 2020, 25, 2880.	3.8	8
160	[ <sup>18</sup> F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2021, 23, 277-286.	2.6	8
161	[ <sup>18</sup> F]ALX5406: A Brain-Penetrating Prodrug for GlyT1-Specific PET Imaging. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3335-3346.	3.5	8
162	Cerebral A1 adenosine receptor availability in female and male participants and its relationship to sleep. <i>NeuroImage</i> , 2021, 245, 118695.	4.2	8

#	ARTICLE	IF	CITATIONS
163	Two Decades of Brain Tumour Imaging with O-(2-[ <sup>18</sup> F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience. <i>Cancers</i> , 2022, 14, 3336.	3.7	8
164	A three-step radiosynthesis of [ <sup>18</sup> F]fluoro-meta-tyrosine starting with [ <sup>18</sup> F]fluoride. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 133-140.	1.0	7
165	Delivery of the Radionuclide <sup>131</sup> I Using Cationic Fusogenic Liposomes as Nanocarriers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 457.	4.1	7
166	Rapid <sup>18</sup> F-labeling <i>via</i> Pd-catalyzed <i>S</i> -arylation in aqueous medium. <i>Chemical Communications</i> , 2021, 57, 3547-3550.	4.1	7
167	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 3183-3183.	8.2	7
168	mGluR5 binding changes during a mismatch negativity task in a multimodal protocol with [ <sup>11</sup> C]ABP688 PET/MR-EEG. <i>Translational Psychiatry</i> , 2022, 12, 6.	4.8	7
169	Investigation of cis-4-[ <sup>18</sup> F]Fluoro-D-Proline Uptake in Human Brain Tumors After Multimodal Treatment. <i>Molecular Imaging and Biology</i> , 2018, 20, 1035-1043.	2.6	6
170	<sup>52</sup> / <sub>55</sub> Mn-Labelled CDTA-based trimeric complexes as novel bimodal PET/MR probes with high relaxivity. <i>Dalton Transactions</i> , 2019, 48, 3003-3008.	3.3	6
171	Influence of incubation conditions on microsomal metabolism of xanthine-derived A1 adenosine receptor ligands. <i>Journal of Pharmacological and Toxicological Methods</i> , 2019, 95, 16-26.	0.7	6
172	Dnmt3a2/Dnmt3L Overexpression in the Dopaminergic System of Mice Increases Exercise Behavior through Signaling Changes in the Hypothalamus. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6297.	4.1	6
173	<sup>18</sup> F-Labeled magnetic nanovectors for bimodal cellular imaging. <i>Biomaterials Science</i> , 2021, 9, 4717-4727.	5.4	6
174	Finding New Communities: A Principle of Neuronal Network Reorganization in Alzheimer's Disease. <i>Brain Connectivity</i> , 2021, 11, 225-238.	1.7	6
175	Optimizing the transfer of [ <sup>18</sup> F]fluoride from aqueous to organic solvents by electrodeposition using carbon electrodes. <i>Applied Radiation and Isotopes</i> , 2014, 91, 1-7.	1.5	5
176	Towards authentically labelled bi-modal PET(SPECT)/MR-probes. <i>EJNMMI Physics</i> , 2014, 1, A79.	2.7	5
177	Isolation of high purity <sup>73</sup> Se using solid phase extraction after selective 4,5-[ <sup>73</sup> Se]benzopiazselenol formation with aminonaphthalene. <i>Radiochimica Acta</i> , 2018, 106, 497-505.	1.2	5
178	In vivo Molecular Imaging of Glutamate Carboxypeptidase II Expression in Re-endothelialisation after Percutaneous Balloon Denudation in a Rat Model. <i>Scientific Reports</i> , 2018, 8, 7411.	3.3	5
179	Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents. <i>BMC Cancer</i> , 2019, 19, 633.	2.6	5
180	Measurement of spallation cross sections for the production of terbium radioisotopes for medical applications from tantalum targets. <i>Nuclear Instruments &amp; Methods in Physics Research B</i> , 2020, 463, 327-329.	1.4	5

#	ARTICLE	IF	CITATIONS
181	Entorhinal Tau Predicts Hippocampal Activation and Memory Deficits in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1601-1614.	2.6	5
182	Radioiodinated indomethacin amide for molecular imaging of cyclooxygenase-2 expressing tumors. <i>Oncotarget</i> , 2017, 8, 18059-18069.	1.8	5
183	Comparison of the Amyloid Load in the Brains of Two Transgenic Alzheimer's Disease Mouse Models Quantified by Florbetaben Positron Emission Tomography. <i>Frontiers in Neuroscience</i> , 2021, 15, 699926.	2.8	5
184	<sup>5</sup> mGluR and <sup>A</sup> GABA receptor-specific parametric <sup>PET</sup> atlas construction" <sup>PET</sup> / <sup>MR</sup> data processing pipeline, validation, and application. <i>Human Brain Mapping</i> , 2022, 43, 2148-2163.	3.6	5
185	Radiosynthesis and Biological Evaluation of [ <sup>18</sup> F]R91150, a Selective 5-HT <sub>2A</sub> Receptor Antagonist for PET-Imaging. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 738-744.	2.8	4
186	Positron-Emission-Tomography Imaging of Long-Term Expression of the 18kDa Translocator Protein After Sudden Cardiac Arrest in Rats. <i>Shock</i> , 2020, Publish Ahead of Print, 620-629.	2.1	4
187	<sup>11</sup> C- and <sup>18</sup> F-labelled tryptophans as PET-tracers for imaging of altered tryptophan metabolism in age-associated disorders. <i>Russian Chemical Reviews</i> , 2020, 89, 879-896.	6.5	4
188	Evaluation of 3-l- and 3-d-[ <sup>18</sup> F]Fluorophenylalanines as PET Tracers for Tumor Imaging. <i>Cancers</i> , 2021, 13, 6030.	3.7	4
189	Positron Emission Intensity in the Decay of <sup>86</sup> gY for Use in Dosimetry Studies. <i>Molecules</i> , 2022, 27, 768.	3.8	4
190	Authentically radiolabelled Mn(II) complexes as bimodal PET/MR tracers. <i>EJNMMI Physics</i> , 2015, 2, A85.	2.7	3
191	Synthesis and Pharmacological Evaluation of Identified and Putative Metabolites of the <sup>1</sup> Adenosine Receptor Antagonist 8-(3-(3-fluoropropyl)propyl)xanthine (CPFPX). <i>ChemMedChem</i> , 2017, 12, 770-784.		3
192	Investigation of Cerebral O-(2-[ <sup>18</sup> F]Fluoroethyl)-L-Tyrosine Uptake in Rat Epilepsy Models. <i>Molecular Imaging and Biology</i> , 2020, 22, 1255-1265.	2.6	3
193	Age and Anterior Basal Forebrain Volume Predict the Cholinergic Deficit in Patients with Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-16.	2.6	3
194	Excitation functions of proton-induced nuclear reactions on <sup>86</sup> Sr, with particular emphasis on the formation of isomeric states in <sup>86</sup> Y and <sup>85</sup> Y. <i>European Physical Journal A</i> , 2022, 58, 1.	2.5	3
195	Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	1.2	3
196	D26...Pathological tau signal in huntington's disease " an in vivo [ <sup>18</sup> F]-AV-1451 pet imaging report. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A44.1-A44.	1.9	2
197	Baeyer-Villiger oxidation tuned to chemoselective conversion of non-activated [ <sup>18</sup> F]fluorobenzaldehydes to [ <sup>18</sup> F]fluorophenols. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 380-392.	1.0	2
198	Bolus infusion scheme for the adjustment of steady state [ <sup>11</sup> C]Flumazenil levels in the grey matter and in the blood plasma for neuroreceptor imaging. <i>NeuroImage</i> , 2020, 221, 117160.	4.2	2

#	ARTICLE	IF	CITATIONS
199	Production of 6-l-[18F]Fluoro-m-tyrosine in an Automated Synthesis Module for 11C-Labeling. <i>Molecules</i> , 2021, 26, 5550.	3.8	2
200	Discovery of F-18-JK-PSMA-7 as PET-probe suitable for imaging of small PSMA expressing lesions. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, .	0.7	2
201	<i>Radiopharmaceutical Sciences.</i> , 2020, , 49-191.		2
202	Imaging of cerebral tryptophan metabolism using 7-[18F]FTp-PET in a unilateral Parkinsonian rat model. <i>NeuroImage</i> , 2022, 247, 118842.	4.2	2
203	Synthesis and biodistribution of 3- <sup>18</sup> F-fluoro-5-[131I]iodo-2-deoxyuridine: a comparative study of [131I]FDU and [18F]FLT. <i>Nuclear Medicine and Biology</i> , 2007, 34, 273-281.	0.6	1
204	Recent Trends in Pharmaceutical Radiochemistry for Molecular PET Imaging. <i>BioMed Research International</i> , 2014, 2014, 1-3.	1.9	1
205	Production of medically useful bromine isotopes via alpha-particle induced nuclear reactions. <i>EPJ Web of Conferences</i> , 2017, 146, 08006.	0.3	1
206	New irradiation facilities for development of production methods of medical radionuclides at cyclotrons at Forschungszentrum Jülich. , 2017, , .		1
207	Influence of binding affinity and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of two novel xanthine PET radioligands for the A1 adenosine receptor. <i>Nuclear Medicine and Biology</i> , 2020, 82-83, 1-8.	0.6	1
208	Development and Evaluation of a Versatile Receptor-Ligand Binding Assay Using Cell Membrane Preparations Embedded in an Agarose Gel Matrix and Evaluation with the Human Adenosine A1Receptor. <i>Assay and Drug Development Technologies</i> , 2020, 18, 328-340.	1.2	1
209	Radiosynthesis and evaluation of 18F-labeled dopamine D4-receptor ligands. <i>Nuclear Medicine and Biology</i> , 2021, 92, 43-52.	0.6	1
210	Species Differences in Microsomal Metabolism of Xanthine-Derived A1 Adenosine Receptor Ligands. <i>Pharmaceuticals</i> , 2021, 14, 277.	3.8	1
211	Towards chronic deep brain stimulation in freely moving hemiparkinsonian rats: applicability and functionality of a fully implantable stimulation system. <i>Journal of Neural Engineering</i> , 2021, 18, 036018.	3.5	1
212	Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of-amyloid plaques. <i>Nuklearmedizin - NuclearMedicine</i> , 2007, , .	0.7	1
213	The role of chemistry in accelerator-based production and separation of radionuclides as basis for radiolabelled compounds for medical applications. <i>Radiochimica Acta</i> , 2022, 110, 707-724.	1.2	1
214	A Practical One-Pot Synthesis of Positron Emission Tomography (PET) Tracers via Nickel-Mediated Radiofluorination. <i>ChemistryOpen</i> , 2015, 4, 395-395.	1.9	0
215	[P200]: <i>IN VIVO</i> TAUOPATHY MEASURED WITH [18F]AV451 IS DIFFERENTIALLY RELATED TO CSF BIOMARKERS OF TAU IN ALZHEIMER'S DISEASE: THE INFLUENCE OF AMYLOID DEPOSITION. <i>Alzheimer's and Dementia</i> , 2017, 13, P683.	0.8	0
216	Heinz H. Coenen – A pioneer in the field of nuclear and radiochemistry. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 122-123.	1.0	0

#	ARTICLE	IF	CITATIONS
217	P05.11 Combined FET PET/MRI radiomics for the differentiation of radiation injury from recurrent brain metastasis. <i>Neuro-Oncology</i> , 2018, 20, iii304-iii304.	1.2	0
218	P1458: LEVEL OF BRAIN RESERVE ASSOCIATED WITH SPATIAL EXTENT OF TAU NEURODEGENERATION PATTERN IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P494.	0.8	0
219	Preparation of 5-[131I]iodotubercidin for the detection of adenosine kinase. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2020, 326, 1691-1697.	1.5	0
220	Synthese und in vitro Evaluierung von F-18-markierten Adenosin-A1-Rezeptor Partialagonisten. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, .	0.7	0
221	Production cross-section measurements of proton-induced reactions on natural tantalum in the 0.3-1.7 GeV energy range. <i>Applied Radiation and Isotopes</i> , 2021, 178, 109983.	1.5	0
222	Imaging in Neurology Research III: Neurodegenerative Diseases. , 2017, , 761-772.		0
223	FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, .	0.7	0
224	Comparison of [18F]-Fluoroethyltyrosine PET and the IDH status with Sodium MRI in Cerebral Gliomas. , 2019, 58, .		0
225	Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis. , 2019, 58, .		0
226	Developments in oncological positron emission tomography/computed tomography assessment. <i>Journal of Thoracic Disease</i> , 2015, 7, E637-9.	1.4	0
227	18F-Labelled probes for non-invasive assessment of the IDH genotype in glioma patients. <i>Nuklearmedizin - NuclearMedicine</i> , 2022, 61, .	0.7	0